Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers

Pharmacological Research

Volumn 85, Issue , 2014, Pages 39-44

  Blandizzi, Corrado ^a   Viscomi, Giuseppe Claudio ^b   Marzo, Antonio ^c   Scarpignato, Carmelo ^d  

^a UNIVERSITY OF PISA   (Italy)

^b Alfa Wassermann SpA   (Italy)

^c Institute for Pharmacokinetic and Analytical Studies SA   (Switzerland)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Bioequivalence; Branded formulation; Generic formulation; Rifaximin

Indexed keywords

GENERIC DRUG; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TABLET; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY EXCRETION; ADOLESCENT; BIOAVAILABILITY; BLOOD; CROSSOVER PROCEDURE; INTESTINE ABSORPTION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUGS, GENERIC; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; RIFAMYCINS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84902540074     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.05.001     Document Type: Article

References (49)

1. R.S. Slavik, P.J. Jewesson, and P. Minghetti Regulatory status of medicinal products for human beings in the European Union. The role of generic products Pharmacol Res 34 1996 3 7
2. EMA The European Agency for the Evaluation of Medicinal Products Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1 2010 Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/01/WC500070039.pdf [accessed 10.03.14]
3. HHS/FDA Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - General considerations 2003 Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm070124.pdf [accessed 10.03.14]
4. World Health Organization Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Annex 7. WHO Technical Report Series, No. 937 2006 Available at: http://www.who.int/ medicines/services/expertcommittees/pharmprep/QAS04-093Rev4-final.pdf [accessed 10.03.14]
5. R.S. Slavik, and P.J. Jewesson Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations Clin Pharmacokinet 42 2003 793 817
6. F. Scaglione, and L. Paraboni Influence of pharmacokinetics/ pharmacodynamics of antibacterials in their dosing regimen selection Expert Rev Anti Infect Ther 4 2006 479 490
7. EMA The European Agency for the Evaluation of Medicinal Products Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. CPMP/EWP/239/95 1995 Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003687.pdf [accessed 10.03.14]
8. V.H. Thomas, S. Bhattachar, L. Hitchingham, P. Zocharski, M. Naath, and N. Surendran et al. The road map to oral bioavailability: an industrial perspective Expert Opin Drug Metab Toxicol 2 2006 591 608
9. S. Hurst, C.M. Loi, J. Brodfuehrer, and A. El-Kattan Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans Expert Opin Drug Metab Toxicol 3 2007 469 489
10. D. Singhal Drug polymorphism and dosage form design: a practical perspective Adv Drug Deliv Rev 56 2004 335 347
11. L.F. Huang, and W.Q. Tong Impact of solid state properties on developability assessment of drug candidates Adv Drug Deliv Rev 56 2004 321 334
12. M.L. Peterson, M.B. Hickey, M.J. Zaworotko, and O. Almarsson Expanding the scope of crystal form evaluation in pharmaceutical science J Pharm Pharm Sci 9 2006 317 326
13. A.Y. Lee, D. Erdemir, and A.S. Myerson Crystal polymorphism in chemical process development Annu Rev Chem Biomol Eng 2 2011 259 280
14. A.J. Aguiar, J. Krc, A.W. Kinkel, and J.C. Samyn Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate J Pharm Sci 56 1967 847 853
15. J.K. Pandit, S.K. Gupta, K.D. Gode, and B. Mishra Effect of crystal form on the oral absorption of phenylbutazone Int J Pharm 21 1984 129 132
16. Y. Kato, and M. Kohketsu Relationship between polymorphism and bioavailability of amobarbital in the rabbit Chem Pharm Bull 29 1981 268 272
17. N. Kimura, H. Fukui, H. Takagaki, E. Yonemochi, and K. Terada Characterisation of polymorphs of a novel quinolinone derivative TA-270 (4-hydroxy-1-methyl-3-octyloxy-sinapinoylamino-2(1H)-quinolinone) Chem Pharm Bull 49 2001 1321 1325
18. J. Bauer, S. Spanton, R. Henry, J. Quick, W. Dziki, and W. Porter et al. Ritonavir: an extraordinary example of conformational polymorphism Pharm Res 18 2001 859 866
19. E. Marchi, L. Montecchi, A.P. Venturini, G. Mascellani, M. Brufani, and L. Cellai 4-Deoxypyrido [1′,2′:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption J Med Chem 28 1985 960 963
20. C. Scarpignato, and I. Pelosini Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential Chemotherapy 51 Suppl. 1 2005 36 66
21. C. Scarpignato, and I. Pelosini Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic Digestion 73 Suppl. 1 2006 13 27
22. European Pharmacopoeia. Rifaximin (Revised Monograph) Suppl. 2011;7.1:2362.
23. G.C. Viscomi, M. Campana, M. Barbanti, F. Grepioni, M. Polito, and D. Confortini et al. Crystal forms of rifaximin and their effect on pharmaceutical properties CrystEngComm 10 2008 1074 1081
24. D.J.W. Grant Theory and origin of polymorphism H.G. Brittain, Polymorphism in pharmaceutical solids 1999 Marcel Dekker New York 1 34
25. B. Rodriguez-Spong, C.P. Price, A. Jayasankar, A.J. Matzger, and N. Rodriguez-Hornedo General principles of pharmaceutical solid polymorphism: a supramolecular perspective Adv Drug Deliv Rev 56 2004 241 274
26. G.C. Viscomi, P. MAffei, V. Lauro, M. Barbanti, D. Confortini, and D. Braga Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining long-lasting effect WHO 1079 2011 70
27. ® (rifaximin polymorph α) in healthy volunteers Dig Liv Dis 42 Suppl. 2 2010 191 192
28. Normix® Summary of Product Characteristics (Revision September 1, 2007), Section 5.1.
29. M. Del Tacca, G. Pasqualetti, A. Di Paolo, A. Virdis, G. Massimetti, and G. Gori et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers Br J Clin Pharmacol 68 2009 34 42
30. A. Marzo Open questions in bioequivalence Pharmacol Res 32 1995 237 240
31. Italian Medicines Agency (AIFA) Marketing authorization of generic rifaximin products. G.U. vol. 263 (Suppl. 247) 2010 Available at: http://www.gazzettaufficiale.it/do/gazzetta/downloadPdf? dataPubblicazioneGazzetta=20101110&numeroGazzetta=263&tipoSerie= SG&tipoSupplemento=SO&numeroSupplemento=247&estensione= pdf&edizione=0 [accessed 10.03.14]
32. A. Marzo Clinical pharmacokinetic registration file for NDA and ANDA procedures Pharmacol Res 36 1997 425 450
33. Food and Drug Administration (FDA) Guidance for industry. ANDAs: pharmaceutical solid polymorphism. Chemistry, manufacturing and controls information 2007 Center for Drug Evaluation and Research (CDER) Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072866.pdf [accessed 10.03.14]
34. D. Braga, F. Grepioni, L. Chelazzi, M. Campana, D. Confortini, and G.C. Viscomi The structure-property relationship of four crystal forms of rifaximin CrystEngComm 14 2012 6404 6411
35. J.S. Cohen Avoiding adverse reactions. Effective lower-dose drug therapies for older patients Geriatrics 55 2000 54 56
36. E. Hickey Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials Curr Opin Drug Discov Dev 10 2007 49 52
37. C.D. Ericsson Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea Drug Saf 29 2006 201 207
38. N.M. Bass, K.D. Mullen, A. Sanyal, F. Poordad, G. Neff, and C.B. Leevy et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med 362 2010 1071 1081
39. Salix Pharmaceuticals Inc Xifaxan™ 550 Prescribing Information 2014 Available at: http://cdn.salix.com/shared/pi/xifaxan550-pi.pdf [accessed 10.03.14]
40. C. Scarpignato, and L. Gatta Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth Aliment Pharmacol Ther 38 2013 1409 1410
41. C. Scarpignato Rifaximin, a poorly absorbed antibiotic. Pharmacology and clinical use 2005 Karger AG Basel 1 132
42. C. Scarpignato, and A. Lanas Bacterial flora in digestive disease. Focus on rifaximin 2006 Karger AG Basel 1 254
43. W.J. Burman, K. Gallicano, and C. Peloquin Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics Clin Pharmacokinet 40 2001 327 341
44. T.R. Frieden, T.R. Sterling, S.S. Munsiff, C.J. Watt, and C. Dye Tuberculosis Lancet 362 2003 887 899
45. N. Girgis, Y. Sultan, R.W. Frenck Jr., A. El-Gendy, Z. Farid, and A. Mateczun Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis Pediatr Infect Dis J 17 1998 816 819
46. L.E. Cuevas, P. Kazembe, G.K. Mughogho, G.S. Tillotson, and C.A. Hart Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin J Infect Dis 171 1995 728 731
47. B. Schwartz, A. Al-Tobaiqi, A. Al-Ruwais, R.E. Fontaine, J. A'ashi, and A.W. Hightower et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis Lancet 1 1988 1239 1242
48. A. Fietta, A. Cascina, F. Meloni, M. Morosini, L. Casali, and L. Bono et al. A 10-year survey of Mycobacterium tuberculosis isolates in Pavia and their drug resistance: a comparison with other Italian reports J Chemother 14 2002 33 40
49. S. Cresti, I. Giordano, E. Donati, R. Giaccherini, A. Barberi, and C. Cellesi Prevalence and chemosusceptibility of Neisseria meningitidis and Haemophilus influenzae in a population of central Italy New Microbiol 26 2003 281 288